Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

COMPLETED

Identifier: CI-TRIAL-00066861
Entity page: /trial/NCT02154490 ↗
Edges: 13

Neighbours: 1 cancers11 drugs
Drawn: 12 of 12 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer condition of …CONDITION_OFderived2 of 2
← condition of	Lung Squamous Cell Carcinoma registry condition “Recurrent Squamous Cell Lung Carcinoma” mapped CURATED_BROADER	—	—	Lung Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
← condition of	Lung Squamous Cell Carcinoma registry condition “Stage IV Squamous Cell Lung Carcinoma AJCC v7” mapped CURATED_BROADER

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer intervention of …INTERVENTION_OFderived11 of 11
← intervention of	Docetaxelsmall molecule registry intervention “Docetaxel” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Durvalumabmonoclonal antibody registry intervention “Durvalumab” (BIOLOGICAL) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Erlotinib Hydrochloridesmall molecule registry intervention “Erlotinib Hydrochloride” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Fexagratinibsmall molecule registry intervention “FGFR Inhibitor AZD4547” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Ipilimumabmonoclonal antibody registry intervention “Ipilimumab” (BIOLOGICAL) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Nivolumabmonoclonal antibody registry intervention “Nivolumab” (BIOLOGICAL) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Palbociclibsmall molecule registry intervention “Palbociclib” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Rilotumumabmonoclonal antibody registry intervention “Rilotumumab” (BIOLOGICAL) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Talazoparibsmall molecule registry intervention “Talazoparib” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Taselisibsmall molecule registry intervention “Taselisib” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Tremelimumabmonoclonal antibody registry intervention “Tremelimumab” (BIOLOGICAL) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer intervention of …INTERVENTION_OFderived11 of 11

← intervention of

Docetaxelsmall molecule

registry intervention “Docetaxel” (DRUG) mapped ALIAS

—

not mapped

Observed

clinicaltrials

graph →

← intervention of

Durvalumabmonoclonal antibody

registry intervention “Durvalumab” (BIOLOGICAL) mapped ALIAS

—